Name	Esophageal cancer
ICD	ICD-11: 2B70

In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene				[1]
Response Summary	The levels of m6A and its regulator HNRNPA2B1 were significantly increased in cancerous tissues of esophageal cancer(ESCA), and overexpression of HNRNPA2B1 promotes ESCA progression via up-regulation of de novo fatty acid synthetic enzymes ACLY and Acetyl-CoA carboxylase 1 (ACC1/ACACA).
Responsed Disease	Esophageal cancer [ICD-11: 2B70]
Target Regulator	Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1)		READER	Regulator Info
Target Regulation	Up regulation
Pathway Response	Metabolic pathways			hsa01100
Cell Process	Fatty acid synthesis
In-vitro Model	TE-10	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1760
	Eca-109	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_6898

In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene				[2]
Response Summary	m6A-RNA immunoprecipitation sequencing revealed that METTL3 upregulates the m6A modification of Adenomatous polyposis coli protein (APC), which recruits YTHDF for APC mRNA degradation. Our findings reveal a mechanism by which the Wnt/Bete-catenin pathway is upregulated in ESCC via METTL3/YTHDF-coupled epitranscriptomal downregulation of APC.
Responsed Disease	Esophageal cancer [ICD-11: 2B70]
Target Regulator	Methyltransferase-like 3 (METTL3)		WRITER	Regulator Info
Target Regulation	Down regulation
Pathway Response	Wnt signaling pathway			hsa04310
	Cell cycle			hsa04110
	Glycolysis / Gluconeogenesis			hsa00010
Cell Process	Glycolysis
In-vitro Model	TE-10	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1760
	TE-1	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1759
	KYSE-70	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1356
	KYSE-450	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1353
	KYSE-410	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1352
	KYSE-30	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1351
	KYSE-180	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1349
	KYSE-150	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1348
	KYSE-140	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1347
	HET-1A	Normal	Homo sapiens	CVCL_3702
In-vivo Model	For the subcutaneous implantation model, 1 × 106 cells were injected subcutaneously into the flank regions of female BALB/c nude mice (4-5 weeks).

In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene				[1]
Response Summary	The levels of m6A and its regulator HNRNPA2B1 were significantly increased in cancerous tissues of esophageal cancer(ESCA), and overexpression of HNRNPA2B1 promotes ESCA progression via up-regulation of de novo fatty acid synthetic enzymes ATP-citrate synthase (ACLY) and ACC1.
Responsed Disease	Esophageal cancer [ICD-11: 2B70]
Target Regulator	Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1)		READER	Regulator Info
Target Regulation	Up regulation
Pathway Response	Metabolic pathways			hsa01100
Cell Process	Fatty acid synthesis
In-vitro Model	TE-10	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1760
	Eca-109	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_6898

In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene				[4]
Response Summary	Up-regulation of FTO is frequently observed in esophageal squamous cell carcinoma tissues, and FTO facilitates cell proliferation and migration in ESCC by up-regulating Collagenase 3 (MMP13).
Responsed Disease	Esophageal squamous cell carcinoma [ICD-11: 2B70.1]
Target Regulator	Fat mass and obesity-associated protein (FTO)		ERASER	Regulator Info
Target Regulation	Up regulation
Cell Process	Cell growth and migration
In-vitro Model	Eca-109	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_6898
	KYSE-150	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1348
	TE-1	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1759
In-vivo Model	Stable down-regulated FTO cells were prepared in Eca-109 and KYSE150 and subcutaneously injected into the flank of nude mouse with 2 × 106 cells per mouse.

In total 4 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene				[5]
Response Summary	Knockdown of YTHDC2 substantially promoted the proliferation rate of esophageal squamous cell carcinoma cells by affecting several cancer-related signaling pathways.
Responsed Disease	Esophageal squamous cell carcinoma [ICD-11: 2B70.1]
Target Regulator	YTH domain-containing protein 2 (YTHDC2)		READER	Regulator Info
Target Regulation	Up regulation
Pathway Response	p53 signaling pathway			hsa04115
	NF-kappa B signaling pathway			hsa04064
	JAK-STAT signaling pathway			hsa04630
Cell Process	Genetic variants
In-vitro Model	KYSE-150	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1348
	KYSE-30	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1351
Experiment 2 Reporting the m6A-centered Disease Response by This Target Gene				[6]
Response Summary	Expression of CDKN1A (p21) was significantly up-regulated in ALKBH5-depleted cells, and m6 A modification and stability of Cyclin-dependent kinase inhibitor 1 (CDKN1A) mRNA were increased by ALKBH5 knockdown. Identify ALKBH5 as the first m6 A demethylase that accelerates cell cycle progression and promotes cell proliferation of ESCC cells, which is associated with poor prognosis of esophageal squamous cell carcinoma patients.
Responsed Disease	Esophageal squamous cell carcinoma [ICD-11: 2B70.1]
Target Regulator	RNA demethylase ALKBH5 (ALKBH5)		ERASER	Regulator Info
Target Regulation	Down regulation
Pathway Response	Cell cycle			hsa04110
Cell Process	Cell cycle
	Cell apoptosis
In-vitro Model	OE21	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_2661
	TE-1	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1759
	TE-5	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1764
	TE-9	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1767
In-vivo Model	The OE21 cells were stably transfected with sh-ALKBH5 (#1), sh-ALKBH5 (#2) or sh-scramble as negative control and injected (2 × 106 cells/mouse in 100 uL volume) subcutaneously into the back of male athymic BALB/c nude mice (6 weeks old, Japan SLC).
Experiment 3 Reporting the m6A-centered Disease Response by This Target Gene				[7]
Response Summary	The elevated FTO in esophageal squamous cell carcinoma decreased m6A methylation of LINC00022 transcript, leading to the inhibition of LINC00022 decay via the m6A reader YTHDF2. LINC00022 directly binds to Cyclin-dependent kinase inhibitor 1 (CDKN1A) protein and promotes its ubiquitination-mediated degradation, thereby facilitating cell-cycle progression and proliferation.
Responsed Disease	Esophageal squamous cell carcinoma [ICD-11: 2B70.1]
Target Regulator	Fat mass and obesity-associated protein (FTO)		ERASER	Regulator Info
Pathway Response	Cell cycle			hsa04110
	Ubiquitin mediated proteolysis			hsa04120
Cell Process	Ubiquitination degradation
	Cell apoptosis
	Decreased G0/G1 phase
In-vitro Model	HET-1A	Normal	Homo sapiens	CVCL_3702
	KYSE-150	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1348
	KYSE-450	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1353
	KYSE-70	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1356
	TE-1	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1759
In-vivo Model	The number of cells inoculated in each mouse was 4 × 106, 1 × 106, 2 × 106 and 1 × 106, respectively.
Experiment 4 Reporting the m6A-centered Disease Response by This Target Gene				[8]
Response Summary	METTL3 modulates the cell cycle of Esophageal squamous cell carcinoma(ESCC) cells through a Cyclin-dependent kinase inhibitor 1 (CDKN1A)-dependent pattern. METTL3-guided m6A modification contributes to the progression of ESCC via the p21-axis.
Responsed Disease	Esophageal squamous cell carcinoma [ICD-11: 2B70.1]
Target Regulator	Methyltransferase-like 3 (METTL3)		WRITER	Regulator Info
Target Regulation	Down regulation
Pathway Response	Cell cycle			hsa04110
Cell Process	Arrest cell cycle at G2/M phase
In-vitro Model	TE-1	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1759
	KYSE-150	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1348
In-vivo Model	Totally 5 × 106 ESCC cells after treatment were administered to randomized animals by the subcutaneous route (right flank) in 200 uL DMEM. Tumor measurement was performed every other day. At study end (at least 3 weeks), the animals underwent euthanasia, and the tumors were extracted for histology.

In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene				[9]
Response Summary	FTO relys on the reading protein YTHDF1 to affect the translation pathway of the Estradiol 17-beta-dehydrogenase 11 (HSD17B11) gene to regulate the formation of lipid droplets in esophageal cancer cells.
Responsed Disease	Esophageal cancer [ICD-11: 2B70]
Target Regulator	Fat mass and obesity-associated protein (FTO)		ERASER	Regulator Info
Target Regulation	Up regulation
Cell Process	Lipid metabolism
In-vitro Model	TE-1	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1759
	KYSE-510	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1354
In-vivo Model	Nude mice were randomly divided into five groups of six mice each, and the mice in each group were received subcutaneous injections of shFTO, scrambled shNC, FTO OE, and vector KYSE510 cells (5×106 tumor cells/mouse), respectively. The tumor size and weight of mice were measured 1 week later, which was recorded as day 0, and then measured once every other day; and the tumor volumes were calculated using the following formula: (length×width2)/2.When the tumor maximum diameter was close to 15 mm, the mice were euthanized and the tumor tissues were collected for immunohistochemistry analysis.

In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene				[5]
Response Summary	Knockdown of YTHDC2 substantially promoted the proliferation rate of esophageal squamous cell carcinoma cells by affecting several cancer-related signaling pathways.
Responsed Disease	Esophageal squamous cell carcinoma [ICD-11: 2B70.1]
Target Regulator	YTH domain-containing protein 2 (YTHDC2)		READER	Regulator Info
Target Regulation	Up regulation
Pathway Response	p53 signaling pathway			hsa04115
	NF-kappa B signaling pathway			hsa04064
	JAK-STAT signaling pathway			hsa04630
Cell Process	Genetic variants
In-vitro Model	KYSE-150	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1348
	KYSE-30	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1351

In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene				[11]
Response Summary	L-glutamine amidohydrolase (GLS2) as a downstream target of METTL3. These findings uncover METTL3/GLS2 signaling as a potential therapeutic target in antimetastatic strategies against esophageal Squamous Cell Carcinoma(ESCC).
Responsed Disease	Esophageal squamous cell carcinoma [ICD-11: 2B70.1]
Target Regulator	Methyltransferase-like 3 (METTL3)		WRITER	Regulator Info
Target Regulation	Up regulation
Cell Process	Cell migration
	Cell invasion
In-vitro Model	HEEC cell line (Normal esophageal epithelial cell line)
	TE-1	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1759
	TE-13	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_4463
	Eca-109	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_6898
	EC/CUHK1	Esophageal carcinoma	Homo sapiens	CVCL_RY08

In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene				[12]
Response Summary	METTL3 could interact with Microprocessor complex subunit DGCR8 (DGCR8) protein and positively modulate pri-miR-320b maturation process in an N6-methyladenosine (m6A)-dependent manner. Therefore, our findings uncover a VEGF-C-independent mechanism of exosomal and intracellular miR-320b-mediated LN metastasis and identify miR-320b as a novel predictive marker and therapeutic target for LN metastasis in ESCC.
Responsed Disease	Esophageal squamous cell carcinoma [ICD-11: 2B70.1]
Target Regulator	Methyltransferase-like 3 (METTL3)		WRITER	Regulator Info
Target Regulation	Up regulation
Pathway Response	PI3K-Akt signaling pathway			hsa04151
Cell Process	Cell proliferation
	Cell migration
	Cell invasion
	Epithelial-mesenchymal transition
In-vitro Model	TE-1	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1759
	KYSE-30	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1351
	KYSE-150	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1348
	HET-1A	Normal	Homo sapiens	CVCL_3702
	CVCL_E307	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_E307
	Eca-109	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_6898
In-vivo Model	Luciferase-labeled KYSE150 cells (5 × 106) were inoculated into the footpads of BALB/c nude mice (4-5 weeks old, 18-20 g) to establish the popliteal lymphatic metastasis model.

In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene				[17]
Response Summary	METTL3-catalyzed m6A modification promotes Neurogenic locus notch homolog protein 1 (NOTCH1) expression and the activation of the Notch signaling pathway. Forced activation of Notch signaling pathway successfully rescues the growth, migration, and invasion capacities of METTL3-depleted ESCC cells.
Responsed Disease	Esophageal squamous cell carcinoma [ICD-11: 2B70.1]
Target Regulator	Methyltransferase-like 3 (METTL3)		WRITER	Regulator Info
Target Regulation	Up regulation
Pathway Response	Notch signaling pathway			hsa04330
Cell Process	Cell migration
	Cell invasion
In-vitro Model	TE-9	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1767
	KYSE-30	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1351
In-vivo Model	For induction of ESCC, 4-week-old mice were treated with drinking water containing 50 ug/mL 4NQO (Sigma-Aldrich, USA) for 16 weeks and then given normal drinking water for another 4-5 weeks. Cre was activated by the intraperitoneal injection of tamoxifen (Sigma-Aldrich, USA) at a dose of 9 mg per 40 g body weight every other day for a total of three injections. For tumor measurement, mice were sacrificed, and the esophagus was dissected immediately. The surface areas of tumors were measured as described previously.

In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene				[20]
Response Summary	METTL3 plays a carcinogenic role in human EC progression partially through RAC-alpha serine/threonine-protein kinase (AKT1) signaling pathways, suggesting that METTL3 serves as a potential therapeutic target for esophageal cancer therapy. A double-effect inhibitor (BEZ235) inhibited AKT and mTOR phosphorylation and hindered the effect of METTL3 overexpression on the proliferation and migration of Eca-109 and KY-SE150 cells.
Responsed Disease	Esophageal cancer [ICD-11: 2B70]
Target Regulator	Methyltransferase-like 3 (METTL3)		WRITER	Regulator Info
Target Regulation	Up regulation
Pathway Response	PI3K-Akt signaling pathway			hsa04151
	Wnt signaling pathway			hsa04310
	mTOR signaling pathway			hsa04150
	Apoptosis			hsa04210
Cell Process	Cell proliferation and invasion
	Cell apoptosis
In-vitro Model	Eca-109	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_6898
	KYSE-150	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1348
	Normal esophageal epithelial cell line (HEEC) (Isolated from the human esophagus)

In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene				[21]
Response Summary	Knockdown of FTO drastically suppressed the proliferation, migration, and invasion of ESCC cells,and Receptor tyrosine-protein kinase erbB-2 (ERBB2) is the target of FTO, which acts in concert in ESCC tumorigenesis and metastasis.
Responsed Disease	Esophageal squamous cell carcinoma [ICD-11: 2B70.1]
Target Regulator	Fat mass and obesity-associated protein (FTO)		ERASER	Regulator Info
Target Regulation	Up regulation
Cell Process	Cell proliferation
	Cell migration
	Cell invasion
In-vitro Model	KYSE-450	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1353
	KYSE-30	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1351
	KYSE-180	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1349
	KYSE-150	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1348
	KYSE-140	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1347
In-vivo Model	For the subcutaneous transplantation model, sh-control, sh-FTO, NC-OE and ERBB2-OE KYSE150 stable cells (6 × 106 per mouse, n = 3 for each group) were diluted to 100 uL PBS + 100 uL Matrigel (BD) and subcutaneously injected to two points in the middle and upper groin of immunodeficient mice to study tumor growth. When the tumor volume reached ~ 1000 mm3 in each group, the nude mice were killed, and the tumors were excised and weighed for histology and further study. The tumor volume was calculated by the formula V = 1/2 × large diameter × (small diameter)2. For a model of lung metastasis in vivo, nude mice were injected with 100 uL WT (wide type), sh-FTO, ERBB2-OE and sh-FTO+ERBB2-OE KYSE150 stable cells (1 × 106 cells per mouse, n = 3 for each group) through tail vein, respectively. Six weeks after injection, the mice were killed and analyzed for metastatic lung tumors.

In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene				[22]
Response Summary	ALKBH5 demethylated pri-miR-194-2 and inhibited miR-194-2 biogenesis through an m6A/DGCR8-dependent manner. ALKBH5/miR-194-2/Retinoic acid-induced protein 1 (RAI1) axis was also validated in clinical samples. This study revealed ALKBH5 in miRNAs biogenesis and provide novel insight for developing treatment strategies in esophageal cancer.
Responsed Disease	Esophageal cancer [ICD-11: 2B70]
Target Regulator	RNA demethylase ALKBH5 (ALKBH5)		ERASER	Regulator Info
Target Regulation	Down regulation

In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene				[5]
Response Summary	Knockdown of YTHDC2 substantially promoted the proliferation rate of esophageal squamous cell carcinoma cells by affecting several cancer-related signaling pathways.
Responsed Disease	Esophageal squamous cell carcinoma [ICD-11: 2B70.1]
Target Regulator	YTH domain-containing protein 2 (YTHDC2)		READER	Regulator Info
Target Regulation	Up regulation
Pathway Response	p53 signaling pathway			hsa04115
	NF-kappa B signaling pathway			hsa04064
	JAK-STAT signaling pathway			hsa04630
Cell Process	Genetic variants
In-vitro Model	KYSE-150	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1348
	KYSE-30	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1351

In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene				[23]
Response Summary	METTL14, an m6A RNA methyltransferase downregulated in ESCC, suppresses Tribbles homolog 2 (TRIB2) expression via miR-99a-5p-mediated degradation of TRIB2 mRNA by targeting its 3' untranslated region, whereas TRIB2 induces ubiquitin-mediated proteasomal degradation of METTL14 in a COP1-dependent manner.
Responsed Disease	Esophageal squamous cell carcinoma [ICD-11: 2B70.1]
Target Regulator	Methyltransferase-like 14 (METTL14)		WRITER	Regulator Info
Target Regulation	Down regulation
Pathway Response	Ubiquitin mediated proteolysis			hsa04120
Cell Process	Proteasome pathway degradation
In-vitro Model	TE-1	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1759
	KYSE-410	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1352
	KYSE-150	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1348
	HET-1A	Normal	Homo sapiens	CVCL_3702
	HEK293T	Normal	Homo sapiens	CVCL_0063
	Eca-109	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_6898
	CVCL_E307	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_E307
In-vivo Model	Fresh PDX tumor samples collected from two established PDX models (PDX #07 with high TRIB2 expression and PDX #12 with low TRIB2, passages three to four) were minced and subcutaneously implanted into the flanks of 3- to 4-week-old female BALB/c nude mice (Jiesijie Laboratory Animals).

In total 2 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene				[7]
Response Summary	The elevated FTO in esophageal squamous cell carcinoma decreased m6A methylation of LINC00022 transcript, leading to the inhibition of Deleted in lymphocytic leukemia 2 (DLEU2/LINC00022) decay via the m6A reader YTHDF2.
Responsed Disease	Esophageal squamous cell carcinoma [ICD-11: 2B70.1]
Target Regulator	YTH domain-containing family protein 2 (YTHDF2)		READER	Regulator Info
Target Regulation	Down regulation
Pathway Response	Cell cycle			hsa04110
	Ubiquitin mediated proteolysis			hsa04120
Cell Process	Ubiquitination degradation
	Cell apoptosis
	Decreased G0/G1 phase
In-vitro Model	HET-1A	Normal	Homo sapiens	CVCL_3702
	KYSE-150	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1348
	KYSE-450	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1353
	KYSE-70	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1356
	TE-1	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1759
In-vivo Model	The number of cells inoculated in each mouse was 4 × 106, 1 × 106, 2 × 106 and 1 × 106, respectively.
Experiment 2 Reporting the m6A-centered Disease Response by This Target Gene				[7]
Response Summary	The elevated FTO in esophageal squamous cell carcinoma decreased m6A methylation of Deleted in lymphocytic leukemia 2 (DLEU2/LINC00022) transcript, leading to the inhibition of LINC00022 decay via the m6A reader YTHDF2.
Responsed Disease	Esophageal squamous cell carcinoma [ICD-11: 2B70.1]
Target Regulator	Fat mass and obesity-associated protein (FTO)		ERASER	Regulator Info
Target Regulation	Down regulation
Pathway Response	Cell cycle			hsa04110
	Ubiquitin mediated proteolysis			hsa04120
Cell Process	Ubiquitination degradation
	Cell apoptosis
	Decreased G0/G1 phase
In-vitro Model	HET-1A	Normal	Homo sapiens	CVCL_3702
	KYSE-150	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1348
	KYSE-450	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1353
	KYSE-70	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1356
	TE-1	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1759
In-vivo Model	The number of cells inoculated in each mouse was 4 × 106, 1 × 106, 2 × 106 and 1 × 106, respectively.

In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene				[24]
Response Summary	Downregulation of YY1BM significantly upregulated eEF2K expression and inhibited apoptosis, thus conferring esophageal squamous cell carcinoma cells more adaptive to nutrient deprivation. Cigarette smoking decreased m6A modification of Long intergenic non-protein coding RNA 278 (LINC00278) and YY1BM translation.
Responsed Disease	Esophageal squamous cell carcinoma [ICD-11: 2B70.1]
Cell Process	Nutrient deprivation
	Cell apoptosis
In-vitro Model	HEK293T	Normal	Homo sapiens	CVCL_0063
	Eca-109	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_6898
	HET-1A	Normal	Homo sapiens	CVCL_3702
	KYSE-30	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1351
	TE-1	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1759
In-vivo Model	Injected YY1BM intratumorally into ESCC tumors grafted in nude mice and analyzed the survival time.

In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene				[25]
Response Summary	Platinum can increase the overall m6A level of esophageal cancer. Small nucleolar RNA host gene 3 (SNHG3)/miR-186-5p, induced by platinum, was involved in regulating m6A level by targeting METTL3. miR-186-5p binds to the 3'UTR of METTL3 to inhibit its expression. Our manuscript has provided clues that regulating m6A level was a novel way to enhance the platinum efficacy.
Responsed Disease	Esophageal cancer [ICD-11: 2B70]
Responsed Drug	Pt		Investigative	Drug Info
Target Regulator	Methyltransferase-like 3 (METTL3)		WRITER	Regulator Info
Target Regulation	Up regulation
Cell Process	Cellular Processes
	Cell growth and death
	Cell apoptosis
In-vitro Model	Eca-9706 (Esophageal carcinoma cell line)
	KYSE-150	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1348
In-vivo Model	Used 1 × 106 SNHG3 knocked down KY-SE150 cells and NC lentivirus to inject into the right flank of mice to generate xenografts.

In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene				[26]
Response Summary	HNRNPC, YTHDF, ZC3H13, YTHDC2, and METTL14 were dysregulated in esophageal cancer tissues. miR-186 interacted with HNRNPC and suppressed the expression of HNRNPC. Four miRNAs (microRNA 186 (MIR186), miR-320c, miR-320d, and miR-320b) were used to construct a prognostic signature, which could serve as a prognostic predictor independent from routine clinicopathological features.
Responsed Disease	Esophageal cancer [ICD-11: 2B70]
Target Regulator	Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC)		READER	Regulator Info
In-vitro Model	HEEC cell line (Normal esophageal epithelial cell line)
	KYSE-30	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1351
	TE-1	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1759

In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene				[22]
Response Summary	ALKBH5 demethylated pri-miR-194-2 and inhibited miR-194-2 biogenesis through an m6A/DGCR8-dependent manner. ALKBH5/miR-194-2/RAI1 axis was also validated in clinical samples. This study revealed ALKBH5 in miRNAs biogenesis and provide novel insight for developing treatment strategies in esophageal cancer.
Responsed Disease	Esophageal cancer [ICD-11: 2B70]
Target Regulator	RNA demethylase ALKBH5 (ALKBH5)		ERASER	Regulator Info
Target Regulation	Down regulation

In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene				[25]
Response Summary	Platinum can increase the overall m6A level of esophageal cancer. SNHG3/hsa-miR-186-5p, induced by platinum, was involved in regulating m6A level by targeting METTL3. miR-186-5p binds to the 3'UTR of METTL3 to inhibit its expression. Our manuscript has provided clues that regulating m6A level was a novel way to enhance the platinum efficacy.
Responsed Disease	Esophageal cancer [ICD-11: 2B70]
Responsed Drug	Pt		Investigative	Drug Info
Target Regulator	Methyltransferase-like 3 (METTL3)		WRITER	Regulator Info
Target Regulation	Up regulation
Cell Process	Cellular Processes
	Cell growth and death
	Cell apoptosis
In-vitro Model	Eca-9706 (Esophageal carcinoma cell line)
	KYSE-150	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1348
In-vivo Model	Used 1 × 106 SNHG3 knocked down KY-SE150 cells and NC lentivirus to inject into the right flank of mice to generate xenografts.

In total 2 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene				[26]
Response Summary	HNRNPC, YTHDF, ZC3H13, YTHDC2, and METTL14 were dysregulated in esophageal cancer tissues. miR-186 interacted with HNRNPC and suppressed the expression of HNRNPC. Four miRNAs (miR-186, miR-320c, miR-320d, and hsa-miR-320b) were used to construct a prognostic signature, which could serve as a prognostic predictor independent from routine clinicopathological features.
Responsed Disease	Esophageal cancer [ICD-11: 2B70]
Target Regulator	Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC)		READER	Regulator Info
In-vitro Model	HEEC cell line (Normal esophageal epithelial cell line)
	KYSE-30	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1351
	TE-1	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1759
Experiment 2 Reporting the m6A-centered Disease Response by This Target Gene				[12]
Response Summary	METTL3 could interact with DGCR8 protein and positively modulate pri-miR-320b maturation process in an N6-methyladenosine (m6A)-dependent manner. Therefore, our findings uncover a VEGF-C-independent mechanism of exosomal and intracellular hsa-miR-320b-mediated LN metastasis and identify miR-320b as a novel predictive marker and therapeutic target for LN metastasis in ESCC.
Responsed Disease	Esophageal squamous cell carcinoma [ICD-11: 2B70.1]
Target Regulator	Methyltransferase-like 3 (METTL3)		WRITER	Regulator Info
Target Regulation	Up regulation
Pathway Response	PI3K-Akt signaling pathway			hsa04151
Cell Process	Cell proliferation
	Cell migration
	Cell invasion
	Epithelial-mesenchymal transition
In-vitro Model	TE-1	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1759
	KYSE-30	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1351
	KYSE-150	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1348
	HET-1A	Normal	Homo sapiens	CVCL_3702
	CVCL_E307	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_E307
	Eca-109	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_6898
In-vivo Model	Luciferase-labeled KYSE150 cells (5 × 106) were inoculated into the footpads of BALB/c nude mice (4-5 weeks old, 18-20 g) to establish the popliteal lymphatic metastasis model.

In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene				[26]
Response Summary	HNRNPC, YTHDF, ZC3H13, YTHDC2, and METTL14 were dysregulated in esophageal cancer tissues. miR-186 interacted with HNRNPC and suppressed the expression of HNRNPC. Four miRNAs (miR-186, hsa-miR-320c, miR-320d, and miR-320b) were used to construct a prognostic signature, which could serve as a prognostic predictor independent from routine clinicopathological features.
Responsed Disease	Esophageal cancer [ICD-11: 2B70]
Target Regulator	Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC)		READER	Regulator Info
In-vitro Model	HEEC cell line (Normal esophageal epithelial cell line)
	KYSE-30	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1351
	TE-1	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1759

In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene				[26]
Response Summary	HNRNPC, YTHDF, ZC3H13, YTHDC2, and METTL14 were dysregulated in esophageal cancer tissues. miR-186 interacted with HNRNPC and suppressed the expression of HNRNPC. Four miRNAs (miR-186, miR-320c, hsa-miR-320d, and miR-320b) were used to construct a prognostic signature, which could serve as a prognostic predictor independent from routine clinicopathological features.
Responsed Disease	Esophageal cancer [ICD-11: 2B70]
Target Regulator	Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC)		READER	Regulator Info
In-vitro Model	HEEC cell line (Normal esophageal epithelial cell line)
	KYSE-30	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1351
	TE-1	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1759

In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene				[23]
Response Summary	METTL14, an m6A RNA methyltransferase downregulated in ESCC, suppresses TRIB2 expression via hsa-miR-99a-5p-mediated degradation of TRIB2 mRNA by targeting its 3' untranslated region, whereas TRIB2 induces ubiquitin-mediated proteasomal degradation of METTL14 in a COP1-dependent manner.
Responsed Disease	Esophageal squamous cell carcinoma [ICD-11: 2B70.1]
Target Regulator	Methyltransferase-like 14 (METTL14)		WRITER	Regulator Info
Target Regulation	Up regulation
Pathway Response	Ubiquitin mediated proteolysis			hsa04120
Cell Process	Proteasome pathway degradation
In-vitro Model	TE-1	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1759
	KYSE-410	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1352
	KYSE-150	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_1348
	HET-1A	Normal	Homo sapiens	CVCL_3702
	HEK293T	Normal	Homo sapiens	CVCL_0063
	Eca-109	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_6898
	CVCL_E307	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_E307
In-vivo Model	Fresh PDX tumor samples collected from two established PDX models (PDX #07 with high TRIB2 expression and PDX #12 with low TRIB2, passages three to four) were minced and subcutaneously implanted into the flanks of 3- to 4-week-old female BALB/c nude mice (Jiesijie Laboratory Animals).

In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene				[30]
Response Summary	The biological characteristics of Circ_SLC7A5 including location, miRNAs binding, m6A modification were analyzed. Our study reveals a novel prognosis biomarker of circ-SLC7A5, providing a preliminary landscape of circRNA expression for detection of esophageal squamous cell carcinoma.
Responsed Disease	Esophageal squamous cell carcinoma [ICD-11: 2B70.1]
In-vitro Model	()
	K150 (Esophageal squamous cell carcinoma)
	K150 (Esophageal squamous cell carcinoma)
	K150 (Esophageal squamous cell carcinoma)
	K150 (Esophageal squamous cell carcinoma)
	K150 (Esophageal squamous cell carcinoma)
	T10	Esophageal squamous cell carcinoma	Homo sapiens	CVCL_RL56
	T12 (Human ESCC cell line)

Ref 1	m(6)A Reader HNRNPA2B1 Promotes Esophageal Cancer Progression via Up-Regulation of ACLY and ACC1. Front Oncol. 2020 Sep 29;10:553045. doi: 10.3389/fonc.2020.553045. eCollection 2020.
Ref 2	METTL3 promotes tumour development by decreasing APC expression mediated by APC mRNA N(6)-methyladenosine-dependent YTHDF binding. Nat Commun. 2021 Jun 21;12(1):3803. doi: 10.1038/s41467-021-23501-5.
Ref 3	The SLC45 gene family of putative sugar transporters. Mol Aspects Med. 2013 Apr-Jun;34(2-3):655-60. doi: 10.1016/j.mam.2012.05.014.
Ref 4	FTO promotes cell proliferation and migration in esophageal squamous cell carcinoma through up-regulation of MMP13. Exp Cell Res. 2020 Apr 1;389(1):111894. doi: 10.1016/j.yexcr.2020.111894. Epub 2020 Feb 6.
Ref 5	Genetic variants in m6A modification genes are associated with esophageal squamous-cell carcinoma in the Chinese population. Carcinogenesis. 2020 Jul 10;41(6):761-768. doi: 10.1093/carcin/bgaa012.
Ref 6	m(6) A demethylase ALKBH5 promotes proliferation of esophageal squamous cell carcinoma associated with poor prognosis. Genes Cells. 2020 Aug;25(8):547-561. doi: 10.1111/gtc.12792. Epub 2020 Jul 1.
Ref 7	RNA m6A demethylase FTO-mediated epigenetic up-regulation of LINC00022 promotes tumorigenesis in esophageal squamous cell carcinoma. J Exp Clin Cancer Res. 2021 Sep 20;40(1):294. doi: 10.1186/s13046-021-02096-1.
Ref 8	The M6A methyltransferase METTL3 regulates proliferation in esophageal squamous cell carcinoma. Biochem Biophys Res Commun. 2021 Nov 26;580:48-55. doi: 10.1016/j.bbrc.2021.05.048. Epub 2021 Oct 5.
Ref 9	m6A demethylase FTO promotes tumor progression via regulation of lipid metabolism in esophageal cancer. Cell Biosci. 2022 May 14;12(1):60. doi: 10.1186/s13578-022-00798-3.
Ref 10	Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518. doi: 10.1021/acs.jmedchem.7b01261. Epub 2018 Feb 12.
Ref 11	METTL3 Promotes Esophageal Squamous Cell Carcinoma Metastasis Through Enhancing GLS2 Expression. Front Oncol. 2021 May 19;11:667451. doi: 10.3389/fonc.2021.667451. eCollection 2021.
Ref 12	Exosomal and intracellular miR-320b promotes lymphatic metastasis in esophageal squamous cell carcinoma. Mol Ther Oncolytics. 2021 Sep 25;23:163-180. doi: 10.1016/j.omto.2021.09.003. eCollection 2021 Dec 17.
Ref 13	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. doi: 10.1038/nrd.2015.37. Epub 2016 Feb 12.
Ref 14	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2030).
Ref 15	Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77. doi: 10.1517/13543784.2014.918604. Epub 2014 May 12.
Ref 16	Clinical pipeline report, company report or official report of Prelude Therapeutics.
Ref 17	METTL3-mediated m(6)A mRNA modification promotes esophageal cancer initiation and progression via Notch signaling pathway. Mol Ther Nucleic Acids. 2021 Jul 21;26:333-346. doi: 10.1016/j.omtn.2021.07.007. eCollection 2021 Dec 3.
Ref 18	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. doi: 10.1021/jm0503749.
Ref 19	Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans. Biochemistry. 1994 Feb 22;33(7):1743-52. doi: 10.1021/bi00173a017.
Ref 20	METTL3 promotes the proliferation and invasion of esophageal cancer cells partly through AKT signaling pathway. Pathol Res Pract. 2020 Sep;216(9):153087. doi: 10.1016/j.prp.2020.153087. Epub 2020 Jun 27.
Ref 21	FTO mediated ERBB2 demethylation promotes tumor progression in esophageal squamous cell carcinoma cells. Clin Exp Metastasis. 2022 Aug;39(4):623-639. doi: 10.1007/s10585-022-10169-4. Epub 2022 May 7.
Ref 22	N(6)-methyladenosine demethylase ALKBH5 suppresses malignancy of esophageal cancer by regulating microRNA biogenesis and RAI1 expression. Oncogene. 2021 Sep;40(37):5600-5612. doi: 10.1038/s41388-021-01966-4. Epub 2021 Jul 26.
Ref 23	A methyltransferase-like 14/miR-99a-5p/tribble 2 positive feedback circuit promotes cancer stem cell persistence and radioresistance via histone deacetylase 2-mediated epigenetic modulation in esophageal squamous cell carcinoma. Clin Transl Med. 2021 Sep;11(9):e545. doi: 10.1002/ctm2.545.
Ref 24	A Novel Micropeptide Encoded by Y-Linked LINC00278 Links Cigarette Smoking and AR Signaling in Male Esophageal Squamous Cell Carcinoma. Cancer Res. 2020 Jul 1;80(13):2790-2803. doi: 10.1158/0008-5472.CAN-19-3440. Epub 2020 Mar 13.
Ref 25	Targeting SNHG3/miR-186-5p reverses the increased m6A level caused by platinum treatment through regulating METTL3 in esophageal cancer. Cancer Cell Int. 2021 Feb 17;21(1):114. doi: 10.1186/s12935-021-01747-9.
Ref 26	Network analysis of miRNA targeting m6A-related genes in patients with esophageal cancer. PeerJ. 2021 Jul 29;9:e11893. doi: 10.7717/peerj.11893. eCollection 2021.
Ref 27	Clinical pipeline report, company report or official report of Actinium Pharmaceuticals.
Ref 28	RNA m(6)A regulates transcription via DNA demethylation and chromatin accessibility. Nat Genet. 2022 Sep;54(9):1427-1437. doi: 10.1038/s41588-022-01173-1. Epub 2022 Sep 7.
Ref 29	High-affinity glutamate transporter GLAST/EAAT1 regulates cell surface expression of glutamine/neutral amino acid transporter ASCT2 in human fetal astrocytes. Neurochem Int. 2006 May-Jun;48(6-7):611-5. doi: 10.1016/j.neuint.2005.12.033. Epub 2006 Mar 3.
Ref 30	Circ-SLC7A5, a potential prognostic circulating biomarker for detection of ESCC. Cancer Genet. 2020 Jan;240:33-39. doi: 10.1016/j.cancergen.2019.11.001. Epub 2019 Nov 5.
Ref 31	Clinical pipeline report, company report or official report of TG Theraputics.
Ref 32	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479).
Ref 33	Company report (FirstString Research)
Ref 34	Drug efflux transporters, MRP1 and BCRP, affect the outcome of hypericin-mediated photodynamic therapy in HT-29 adenocarcinoma cells. Photochem Photobiol Sci. 2009 Dec;8(12):1716-23.
Ref 35	Role of transporter-mediated efflux in the placental biodisposition of bupropion and its metabolite, OH-bupropion. Biochem Pharmacol. 2010 Oct 1;80(7):1080-6. doi: 10.1016/j.bcp.2010.06.025. Epub 2010 Jun 23.